Talk Details · IDC 2027

Injectable platelet-rich fibrin (i-PRF) with topical 5% minoxidil versus microneedling with topical 5% minoxidil in male androgenetic alopecia: A tertiary care hospital-based randomised controlled trial

Oral · In-Person · Day 1

Abstract

About this talk

Introduction: Androgenetic alopecia (AGA) is the commonest cause of hair loss in men and carries a considerable psychosocial burden. Topical 5% minoxidil remains the cornerstone of therapy, and adjuvant procedures may further augment its effect. Microneedling is supported by randomised evidence, whereas injectable platelet-rich fibrin (i-PRF), a sustained-release autologous growth-factor concentrate, has been evaluated chiefly in uncontrolled studies. To our knowledge, no randomised trial has directly compared the two as adjuncts to minoxidil.

Objective: To compare the efficacy of i-PRF and microneedling, each combined with topical 5% minoxidil, in men with Hamilton–Norwood grade III to V AGA, using trichoscopic hair density and global photographic assessment, and to evaluate the response by grade, maintenance of response, quality of life, patient satisfaction and safety.

Materials and Methods: This prospective, parallel-group, open-label, hospital-based randomised controlled trial enrolled 60 men aged 18 to 50 years. The calculated sample size was 30 per arm. Participants were allocated by computer-generated block randomisation to monthly intradermal i-PRF or monthly microneedling with a 1.5 mm dermaroller for six months, both with twice-daily topical 5% minoxidil, followed by six months of topical minoxidil alone. Trichoscopic hair density (hairs/cm²), standardised global photographic assessment, Dermatology Life Quality Index (DLQI) and patient satisfaction on a visual analogue scale (VAS) were recorded at baseline, 6 and 12 months, and adverse effects at every visit.

Results: Sixty patients (mean age 25.0 ± 4.2 years) were randomised, and 58 completed 12 months (30 in the i-PRF group and 28 in the microneedling group). Hair density increased significantly in both groups, from 153.50 ± 15.91 to 186.00 ± 22.39 hairs/cm² with i-PRF and from 149.57 ± 11.55 to 186.11 ± 19.72 hairs/cm² with microneedling (gains of 32.5 and 36.5 hairs/cm² respectively; both p < 0.001), without a significant difference between the groups (p = 0.258). A moderate or great photographic improvement was seen in 40% with i-PRF versus 71% with microneedling (p = 0.016). The response was greatest in grade III and least in grade V disease, and was maintained during the six months on minoxidil alone. The DLQI fell by 3.4 versus 4.5 points (p = 0.005), and mean satisfaction at 12 months was 6.5 versus 8.1 (p < 0.001). Mild pain lasting two to three hours was reported by five patients in the microneedling group, with no discontinuation.

Discussion/Conclusion: Both i-PRF and microneedling are effective and well-tolerated adjuvants to topical 5% minoxidil in male AGA, and the benefit persists on minoxidil alone. i-PRF was not superior to microneedling, which produced at least an equal gain in hair density and a better photographic result, quality-of-life improvement and satisfaction. Being simpler and less costly, microneedling is a suitable first-line adjuvant procedure, while i-PRF remains a reasonable alternative for patients who decline or cannot tolerate it. The open-label design, single-centre setting, exclusively male population are limitations; larger blinded trials are needed.

Keywords: androgenetic alopecia, injectable platelet-rich fibrin, microneedling, minoxidil, randomised controlled trial.

Speaker

About the speaker

Farkhanda Sofi

Farkhanda Sofi

All India Institute of Medical Sciences, Gorakhpur, India

View full speaker profile →

Join the IDC 2027 delegation

Rome · June 21–23, 2027 · Hybrid · in-person & virtual

Register as Delegate →

Attend without presenting.